Differences in the incidence and mortality rate of prostate cancer between the USA and
Japan have been decreasing over time, and were only twofold in 2017. Therefore …

Screening for prostate cancer remains a contentious issue. As with other cancer screening
programs, a key feature of the debate is verification of cancer-specific mortality reductions …

Key Clinical Points Prostate-Cancer Screening The introduction of prostate-specific antigen
(PSA) testing has nearly doubled the lifetime risk of receiving a diagnosis of prostate cancer …

Introduction for screening for prostate cancer as a healthcare policy is desirable provided its
effectiveness can be shown in terms of decreasing prostate cancer mortality at an …

Prostate cancer is a major healthcare problem worldwide, especially in the industrialized
countries of the Western world. Prostate cancer has become the most common type of …

The debate about usefulness of population-based prostate cancer screening has been
ongoing for decades, with little consensus among professional medical societies, cancer …

An estimated 220,900 new cases of prostate cancer were diagnosed in the United States in
2003, and 28,900 men died of the disease during that year [1]. A global effort to decrease …

Task Force (USPSTF) states that evidence is insufficient to assess the risks and benefits of
prostate cancer screening in men younger than 75 years. Other major international health …

Prostate cancer is the most common cancer and the second leading cause of cancer-related
deaths in American men. Although the use of the prostate-specific antigen (PSA) test for …

OBJECTIVE• To determine whether screening for prostate cancer reduces prostate cancer‐
specific mortality, impact on all‐cause mortality and patient health‐related quality of life …